Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules

British Journal of Dermatology

Volumn 139, Issue 6, 1998, Pages 965-973

  Hedley, S J ^a   Metcalfe, R ^a   Gawkrodger, D J ^b   Weetman, A P ^a   Mac Neil, S ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOCYTE; PRIORITY JOURNAL; VITILIGO;

ADULT; AGED; CELL COUNT; CELL DIVISION; CELLS, CULTURED; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MELANOCYTES; MIDDLE AGED; VITILIGO;

EID: 0032406986     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02550.x     Document Type: Article

References (61)

1. Le Poole IC, Das PK, van den Wijngaard RMJGJ et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2: 145-53.
2. Le Poole C, Boissy RE. Vitiligo. Semin Cutan Med Surg 1997; 16: 3-14.
3. Gawkrodger DJ. Vitiligo. In. Endocrine Autoimmunity and Related Conditions (Weetman AP, ed.). Dordrecht: Kluwer, 1998, in press.
4. Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI. Autoimmune vitiligo: detection of antibodies to melanin-producing cells. N Engl J Med 1977; 297: 634-7.
5. Naughton GK, Esinger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158: 246-51.
6. Cui J, Harning R, Henn M, Bystryn JC. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98: 162-5.
7. Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993; 100: 823-8.
8. Merimsky O, Shoenleld R, Yecheskel G et al. Vitiligo-and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994; 38: 411-6.
9. Hann S-K, Kim J-B. Detection of antibodies to human melanoma cell in vitiligo by Western blot analysis. Yonsei Med J 1995; 36: 457-61.
10. Song YH, Connor E, Li Y et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1997; 344: 1049-52.
11. Baharav E, Merimski O, Sheonfeld R et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996; 105: 84-8.
12. 35S-labelled recombinant human tyrosinase in radioimmunoassay. J Invest Dermatol 1997; 109: 69-73.
13. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997; 109: 495-500.
14. Norris DA, Kissinger RM, Naughton GM, Bystryn J-C. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90: 783-9.
15. Park YK, Hann SK, Song MS et al. The activity of antimelanocyte autoantibodies in vitiligo patients. Kor J Dermatol 1991; 29: 130-5.
16. Cui J, Arita Y, Bystryn J-C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100: 812-15.
17. Abdel-Naser MD, Kruger-Krasagkes S, Krasagakis K et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994; 7: 1-8.
18. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978-81.
19. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-80.
20. Gilhar A, Zelickson B, Ulmun Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105: 683-6.
21. Cunliffe WJ, Hall R, Newell DJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968; 80: 135-9.
22. Hegedus L, Heidenheim M, Gervil M et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol (Stockh) 1994; 74: 120-3.
23. Schallreuter KU, Lemke R, Brandt O et al. Vitiligo and other diseases - coexistence or true association - Hamburg study on 321 patients. Dermatology 1994; 188: 269-75.
24. Dawber RPR. Vitiligo in mature onset diabetes mellitus. Br J Dermatol 1968; 80: 275-8.
25. Dunlop D. Eighty-six cases of Addison's disease. Br Med J 1963; ii: 887-91.
26. Ahn SK, Choi E, Lee SH et al. Immunohistochemical studies from vitiligo. Comparison between active and inactive lesions. Yonsei Med J 1994; 35: 404-10.
27. Yagi H, Tokura Y, Furukawa F, Takigawa M. Vitiligo with raised inflammatory borders: involvement of T cell immunity and keratinocytes expressing MHC class II and ICAM-1 molecules. Eur J Dermatol 1997; 7: 19-22.
28. Al Badri AMT, Foulis AK, Todd PM et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993; 169: 203-6
29. Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch Ophthalmol 1991; 109: 1270-4.
30. Le Poole IC, van den Wijngaard RMJGJ, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocytes disappearance. Am J Pathol 1996; 148: 1214-28.
31. Metzker A, Zamir R, Gazit E et al. Vitiligo and the HLA system. Dermatologica 1980; 160: 100-5.
32. Dunston GM, Halder RM. Vitiligo is associated with HLA-DR4 in black patients. Arch Dermatol 1990; 126: 56-60.
33. Poloy A, Tibor L, Kramer R et al. HLA DR1 is associated with vitiligo. Immunol Lett 1991; 27: 59-62.
34. Orecchia GL, Perfetti L, Malagoli P et al. Vitiligo is associated with a significant increase in HLA-A 30, Cw6 and Dqw 3 and a decrease in C4AQ0 in Northern Italian patients. Dermatology 1992; 185: 123-7.
35. Ando I, Chi HI, Nakagawa H, Otsuka F. Differences in clinical features and HLA antigens between familial and non-familial vitiligo of non-segmental type. Br J Dermatol 1993; 129: 408-10.
36. Schallreuter KU, Levenig C, Kuhnl P et al. Histocompatibility antigens in vitiligo: Hamburg study on 102 patients from Northern Germany. Dermatology 1993; 187: 186-92.
37. Al-Fouzan A, Al-Arbash M, Fouad F et al. Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur J Immunogenet 1995; 22: 209-13.
38. Venkataram MN, White AG, Leeny WA et al. HLA antigens in Omani patients with vitiligo. Clin Exp Dermatol 1995; 20: 35-7.
39. Buc M, Busova B, Hegyi E, Kolibasova K. Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak population. Folia Biologica 1996; 42: 23-5.
40. Le Poole IC, Mutis T, van den Wijngaard RMJGJ et al. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 1993; 151: 7284-92.
41. Hedley SJ, Gawkrodger DJ, Weetman P, Mac Neil S. Investigation of the influence of extracellular matrix proteins on normal human melanocyte morphology and melanogenic activity. Br J Dermatol 1996; 135: 888-97.
42. Rao J, Otto WR. Fluorimetric DNA assay for cell growth estimation. Anal Biochem 1992; 207: 186-92.
43. Hedley SJ, Gawkrodger DJ, Weetman AP et al. α-Melanocyte stimulating hormone inhibits tumour necrosis factor-α stimulated intercellular adhesion molecule-1 expression in normal cutaneous human melanocytes and in melanoma cell lines. Br J Dermatol 1998; 138: 536-43.
44. Yohn JJ, Critelli M, Lyons MB, Norris DA. Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol 1990; 95: 233-7.
45. Kirnbauer R, Charvat B, Schauer E et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNFβ, and UVB light. J Invest Dermatol 1992; 98: 320-6.
46. Krasagakis K, Garbe C, Eberle J, Orfanos CE. Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Arch Dermatol Res 1995; 287: 259-65.
47. Smit NPM, Le Poole IC, van den Wijngaard R et al. Expression of different immunological markers by cultured human melanocytes. Arch Dermatol Res 1993; 285: 356-65.
48. Tsujisaki M, Igarashi M, Sakaguchi K et al. Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol 1987; 138: 1310-16.
49. Marincola FM, Shamamian P, Alexander RB et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153: 1225-37.
50. Moseley RP, Brown JI, Auld J et al. An immunocytochemical study of MHC class I expression on human Langerhans cells and melanocytes. J Pathol 1997; 181: 419-25.
51. Daar AS, Fuggle V, Fabre JW et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38: 287-92.
52. Eisinger M, Marko O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 1982; 79: 2018-22.
53. Puri N, Mojamdar M, Ramaiah A. In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects. J Invest Dermatol 1987; 88: 434-8.
54. Puri N, Mojamdar M, Ramaiah A. Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in vitro. Arch Dermatol Res 1989; 281: 178-84.
55. Medrano EE, Nordlund JJ. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95: 441-5.
56. Abdel-Malek ZA, Swope VB, Nordlund JJ, Medrano EE. Proliferation and propagation of human melanocytes in vitro are affected by donor age and anatomical site. Pigment Cell Res 1994; 7: 116-22.
57. Im S, Hann SK, Kim HI et al. Biologic characteristics of cultured human vitiligo melanocytes. Int J Dermatol 1994; 33: 556-62.
58. Boissy RE, Liu Y-Y, Medrano EE, Nordlund JJ. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97: 395-404.
59. Bessou S, Gauthier Y, Surlève-Bazielle J et al. Epidermal reconstructs in vitiligo: an extrinsic factor is needed to trigger the disease. Br J Dermatol 1997; 137: 890-7.
60. Le Poole IC, van den Wijngaard RMJGJ, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol 1997; 137: 171-8.
61. Maresca V, Roccella M, Roccella F et al. Increased sensitivity of perioxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997; 109: 310-13.